Adverse reactions similar to placebo

Adverse reactions (ARs) occurring in at least 2% and at a frequency greater than placebo

Placebo(n=984) UBRELVY 50 mg (n=954) UBRELVY 100 mg (n=485)
Nausea 2% 2% 4%
Somnolence 1% 2% 3%
Dry Mouth 1% <1% 2%
Table includes ARs from ACHIEVE I and II.
  • The incidence of ARs in controlled clinical trials was not affected by gender or age2
  • The long-term safety of UBRELVY was further established in 813 patients in a 52-week, open-label trial, with 31,968 doses given3
  • UBRELVY is not a controlled substance, and has not been shown to be habit-forming
  • No cardiovascular warnings and precautions
  • No MOH warnings or precautions*

MOH=medication overuse headache.

*In regard to MOH and other safety concerns, the safety of treating more than 8 migraines in a 30-day period has not been established.

References

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2021. 2. Data on file. Allergan. 3. Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141-152.